Adjunctive zonisamide for treatment refractory anxiety

International Journal of Clinical Practice

Volumn 61, Issue 6, 2007, Pages 1050-1053

  Kinrys, G ^a,b,c   Vasconcelos E Sa, D ^a,b   Nery, F ^a,b  

^a Bipolar Disorder Research Program   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CAMBRIDGE HEALTH ALLIANCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; CLONAZEPAM; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; PAROXETINE; PHENELZINE; QUETIAPINE; SERTRALINE; TRAZODONE; VENLAFAXINE; ZONISAMIDE;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DIZZINESS; DRUG TOLERABILITY; FATIGUE; FEMALE; HAMILTON ANXIETY SCALE; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; XEROSTOMIA;

ADULT; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; COHORT STUDIES; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PILOT PROJECTS; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34248337817     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01365.x     Document Type: Article

References (16)

1. Kessler RC, McGonagle KA, Zhao S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994 51 : 8 19.
2. Ballenger JC. Current treatment of the anxiety disorders in adults. Biol Psychiatry 1999 46 : 1579 94.
3. Clark RD, Canive JM, Calais LA, Qualls CR, Tuason VB. Divalproex in posttraumatic stress disorder: an open-label clinical trial. J Trauma Stress 1999 12 : 395 401.
4. Pande AC, Davidson JR, Jefferson JW et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999 19 : 341 8.
5. Kinrys G, Pollack MH, Simon NM, Worthington JJ, Nardi AE, Versiani M. Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol 2003 18 : 169 72.
6. Kinrys G Worthington J, Wygant LF, Reese H, Simon N, Pollack MH. Presented at the Collegium Internationale Neuropharmacologium (CINP), Paris, 2004.
7. Stahl SM. Symptoms and circuits, part 2: anxiety disorders. J Clin Psychiatry 2003 64 : 1408 9.
8. Stahl SM. Psychopharmacology of anticonvulsants: do all anticonvulsants have the same mechanism of action J Clin Psychiatry 2004 65 : 149 50.
9. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 2002 51 : 31 71.
10. Schauf CL. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res 1987 413 : 185 8.
11. Suziki S, Kawakami K, Nishimura S et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 1992 12 : 21 7.
12. Kito M, Maehara M, Watanabe K. Antiepileptic drugs - calcium current interaction in cultured human neuroblastoma cells. Seizure 1994 3 : 141 9.
13. Okada M, Kaneko S, Hirano T et al. Effects of zonisamide on dopaminergic system. Epilepsy Res 1995 22 : 193 205.
14. Okada M, Hirano T, Kawata Y et al. Biphasic effects of zonisamide on serotoninergic system in rat hippocampus. Epilepsy Res 1999 34 : 187 97.
15. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ. Zonisamide: a new antiepileptic drug. Pol J Pharmacol 2003 55 : 683 9.
16. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res 2001 43 : 11 58.